Laboratory of Neurobiology of Psychiatric Disorders
Research profile
The Laboratory of Neurobiology of Psychiatric Disorders was established in 2010 to conduct extensive research regarding the significance of trace elements in the regulation of central nervous system function, in particular their role in the development and therapy of affective disorders.
The principal objective of our research is zinc. For over a decade we have been studying the importance of this bioelement in the pathophysiology and treatment of depression. Our studies have demonstrated that zinc exhibits antidepressant-like properties and may positively modulate / enhance the activity of other antidepressants. Currently, we are investigating the neurobiological and behavioral aspects of zinc deficiency as a potential new animal model of depression.
Our laboratory closely cooperates with other scientific units (including AGH University of Science and Technology, Department of Psychiatry Jagiellonian University Medical College (UJCM), Department of Pharmacobiology UJCM, Faculty of Chemistry UJ, the Institute of Forensic Research, Medical University of Lublin, the Center for Microelectronics and Nanotechnology University of Rzeszów). Through this collaboration we are developing new experimental methods and techniques enabling more comprehensive and multidimensional research approach.
-
Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.
Monika Woźniak, Francine Acher, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Andrzej Pilc, Joanna M Wierońska
Current neuropharmacology,
PMID:26769224 -
Neurochemical and behavioral studies on the 5-HT1A-dependent antipsychotic action of the mGlu4 receptor agonist LSP4-2022.
Monika Woźniak, Krystyna Gołembiowska, Karolina Noworyta-Sokołowska, Francine Acher, Paulina Cieślik, Magdalena Kusek, Krzysztof Tokarski, Andrzej Pilc, Joanna M Wierońska
Neuropharmacology, S0028-3908(16)30278-7 10.1016/j.neuropharm.2016.06.025
PMID:27465045 -
Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment.
Joanna M Wierońska, Stevin H Zorn, Dario Doller, Andrzej Pilc
Pharmacology & therapeutics, S0163-7258(15)00199-0 10.1016/j.pharmthera.2015.10.007
PMID:26549541 -
mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia.
Joanna M Wierońska, Natalia Kłeczek, Monika Woźniak, Piotr Gruca, Magdalena Łasoń-Tyburkiewicz, Mariusz Papp, Piotr Brański, Grzegorz Burnat, Andrzej Pilc
Neurochemistry international, 10.1016/j.neuint.2015.03.010 S0197-0186(15)00061-3
PMID:25863284 -
Is the mGlu5 receptor a possible target for new antidepressant drugs?
Agnieszka Pałucha-Poniewiera, Joanna M Wierońska, Piotr Brański, Grzegorz Burnat, Barbara Chruścicka, Andrzej Pilc
Pharmacological reports : PR,
PMID:24552998 -
The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.
Joanna M Wierońska, Anna Sławińska, Magdalena Łasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Stevin H Zorn, Darío Doller, Natalia Kłeczek, Karolina Noworyta-Sokołowska, Krystyna Gołembiowska, Andrzej Pilc
Psychopharmacology, 10.1007/s00213-014-3657-4
PMID:25012236 -
The antidepressant-like action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent.
Agnieszka Pałucha-Poniewiera, Piotr Brański, Joanna M Wierońska, Katarzyna Stachowicz, Anna Sławińska, Andrzej Pilc
Psychopharmacology,
PMID:23958941 -
The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Anna Sławińska, Joanna M Wierońska, Katarzyna Stachowicz, Marcin Marciniak, Magdalena Lasoń-Tyburkiewicz, Piotr Gruca, Mariusz Papp, Magdalena Kusek, Krzysztof Tokarski, Darío Doller, Andrzej Pilc
British journal of pharmacology, 10.1111/bph.12254
PMID:23714045 -
The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu₂/₃ receptor agonist, LY379268, is 5-HT₁A dependent.
Joanna M Wierońska, A Sławińska, K Stachowicz, M Łasoń-Tyburkiewicz, P Gruca, M Papp, A Pilc
Behavioural brain research, 10.1016/j.bbr.2013.08.007 S0166-4328(13)00483-X
PMID:23948211 -
Glutamate-based anxiolytic ligands in clinical trials.
Joanna M Wierońska, Andrzej Pilc
Expert opinion on investigational drugs, 10.1517/13543784.2013.803066
PMID:23718208 -
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT₁A signalling.
Joanna M Wierońska, Francine C Acher, Anna Sławińska, Piotr Gruca, Magdalena Lasoń-Tyburkiewicz, Mariusz Papp, Andrzej Pilc
Psychopharmacology, 10.1007/s00213-013-3005-0
PMID:23474845 -
Glutamate-based antidepressants: preclinical psychopharmacology.
Andrzej Pilc, Joanna M Wierońska, Phil Skolnick
Biological psychiatry, 10.1016/j.biopsych.2013.01.021 S0006-3223(13)00092-9
PMID:23453290 -
The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice.
J M Wierońska, M Kusek, K Tokarski, J Wabno, W Froestl, A Pilc
British journal of pharmacology, 10.1111/j.1476-5381.2011.01301.x
PMID:21371011 -
Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.
Joanna M Wierońska, Katarzyna Stachowicz, Francine Acher, Tomasz Lech, Andrzej Pilc
Psychopharmacology, 10.1007/s00213-011-2502-2
PMID:21952670 -
On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice.
J M Wierońska, K Stachowicz, P Brański, A Pałucha-Poniewiera, A Pilc
Neuropharmacology, 10.1016/j.neuropharm.2011.07.042
PMID:21855555
